NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

No, this isn't just another cancer treatment. This is an emerging class of treatments where BP is not in the forefront. There is so much learned every day about these immunology details that the chances this basic approach proves worthy is extremely high, even if the current versions do not show efficacy, yet BP passed on the entire class of therapies. They very likely did so because they thought it would be too expensive, not because they thought it would never work.

I think cost matters a great deal. I'm not saying that being worried about that is evil. But that is for the insurance companies to deal with. I understand why they would not want to be in the position of having tell people that a demonstrated therapy/possible-subgroup-cure is too expensive... but that is how this works, if in fact, the costs prove to be very high. I think they, long ago, planned to nip this oak tree in the acorn, and I think that is what might be going on now.